On the basis of this, EGFR testing should be considered for adjuvant osimertinib therapy for lung adenocarcinoma.23 Currently, osimertinib is not approved for the adjuvant setting in Colombia. This evidence concerns the gene EGFR and lung adenocarcinoma.